科研之友
微信
新浪微博
Facebook
分享链接
摘要
With China's aspiration of building a healthy nation and increasing its average life expectancy, the pharmaceutical industry will continue to grow in the coming years. Considering the high energy consumption and emissions in the pharmaceutical industry, striving for sustainability will be essential to achieving the 2030 target of peaking CO2 emissions and becoming carbon neutral by 2060. This paper quantifies the reduction potential for CO2 emissions in the pharmaceutical industry to provide policymakers with some references when decomposing the reduction task. By constructing a non-radical metafrontier Malmquist CO2 performance index (NMMCPI), we find that the NMMCPI in the pharmaceutical industry is improved from 2005 to 2016. The three main factors influencing the changes are technical efficiency, technological advancement and technological leadership. These three factors have contributed to the growth of NMMCPI in the eastern Chinese pharmaceutical industry; however, the technological leadership effect is lacking in central and western China. There is a huge CO2 emissions reduction potential in the pharmaceutical industry, which can be compared to UK and Brazilian emissions in 2016. In light of this, we recommend some policy implications to reduce the CO2 emissions of the pharmaceutical industry in the future.
-
单位南京理工大学
